1 INDICATIONS AND USAGE SODIUM CITRATE 4 % W / V ANTICOAGULANT SOLUTION is intended for use only for the anticoagulation of whole blood as part of automated apheresis procedures .
[ See Dosage and Administration ( 2 ) . ]
SODIUM CITRATE 4 % W / V ANTICOAGULANT SOLUTION USP is intended for use only for the anticoagulation of whole blood as part of automated apheresis procedures .
( 1 ) 2 DOSAGE AND ADMINISTRATION • SODIUM CITRATE 4 % ANTICOAGULANT SOLUTION USP is added to tubing sets during apheresis procedures .
( 2 ) • SODIUM CITRATE 4 % ANTICOAGULANT SOLUTION USP may only be used with apheresis devices .
For instructions on the use of the solution see the apheresis device operator ' s manual .
( 2 . 1 ) • Follow the directions for connecting the SODIUM CITRATE 4 % ANTICOAGULANT SOLUTION USP bag to the apheresis system .
( 2 . 2 ) 2 . 1 General Dosing Information SODIUM CITRATE 4 % W / V ANTICOAGULANT SOLUTION USP is added to tubing sets during apheresis procedures .
The solution is connected the tubing set in an apheresis collection .
The recommended dose is determined by the apheresis device and metered into the tubing set by the apheresis device .
It is not intended for direct intravenous infusion .
For instructions on the use of the solution with the apheresis device and tubing set , see the device operator ' s manual .
2 . 2 Administration • Ensure solution is the SODIUM CITRATE 4 % W / V ANTICOAGULANT SOLUTION USP and is within the expiration date .
• Inspect the bag .
Do not use if the container is damaged , leaking or if there is any visible sign of deterioration .
• Use only if solution is clear and free of particulate matter .
• Protect from sharp objects .
Directions for connecting the SODIUM CITRATE 4 % W / V ANTICOAGULANT SOLUTION USP bag to the apheresis device .
At the prompt to connect anticoagulant to the apheresis device tubing set : • Remove the overwrap by pulling down at the notch , and remove the SODIUM CITRATE 4 % W / V ANTICOAGULANT SOLUTION USP bag .
• Before use , perform the following checks [ See Warnings and Precautions ( 5 ) . ]
: • Check for leaks by gently squeezing the bag .
If leaks are found , discard the bag .
• Ensure that the solution is the SODIUM CITRATE 4 % W / V ANTICOAGULANT SOLUTION USP and is within the expiration date .
• Inspect the solution in good light .
Bags showing cloudiness , haze , or particulate matter should not be used .
• Remove the protective cap from the port on the bag .
• Connect the bag to the apheresis device tubing set using aseptic technique and hang the solution .
• Proceed according to the apheresis device operator ' s manual .
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration , whenever the solution and container permit .
3 DOSAGE FORMS AND STRENGTHS 250 mL SODIUM CITRATE 4 % W / V ANTICOAGULANT SOLUTION USP is a sterile solution in a PVC bag .
Each 100 mL contains : Sodium Citrate ( dihydrate ) 4 . 0 g ; and 100 mL Water for Injection , ( pH adjusted with citric acid ) .
• 250 mL sterile fluid in a PVC bag .
( 3 ) 4 CONTRAINDICATIONS DO NOT INFUSE SODIUM CITRATE 4 % W / V ANTICOAGULANT SOLUTION USP DIRECTLY TO THE DONOR .
• DO NOT INFUSE SODIUM CITRATE 4 % W / V ANTICOAGULANT SOLUTION USP DIRECTLY TO THE DONOR .
( 4 ) 5 WARNINGS AND PRECAUTIONS • Verify that the SODIUM CITRATE 4 % W / V ANTICOAGULANT SOLUTION USP has been securely attached to the Anticoagulant ( AC ) line on the system tubing set .
Use aseptic technique throughout all procedures to ensure donor safety and quality .
• Do not reuse .
Discard unused or partially used solution bags .
• Verify that the SODIUM CITRATE 4 % W / V ANTICOAGULANT SOLUTION USP has been securely attached to the Anticoagulant ( AC ) line on the system tubing set .
Use aseptic technique throughout all procedures to ensure donor safety and quality .
( 5 ) 6 ADVERSE REACTIONS Citrate reactions or toxicity may occur with the infusion of blood products to patients and return of blood containing citrate anticoagulant to donors .
The recipient of the blood containing citrate should be monitored for the signs and symptoms of citrate toxicity .
The signs and symptoms of citrate toxicity begin with paresthesia , a " tingling " sensation around the mouth or in the extremities , followed by severe reactions that are characterized by hypotension and possible cardiac arrhythmia .
Citrate toxicity may occur more frequently in patients who are hypothermic , have impaired liver or renal function , or have low calcium levels because of an underlying disease .
Citrate reactions or toxicity may occur with the infusion and return of blood containing citrate anticoagulant .
The recipient of the blood containing citrate should be monitored for the signs and symptoms of citrate toxicity .
( 6 ) To report SUSPECTED ADVERSE REACTIONS , contact Terumo BCT , Inc . at 1 - 877 - 339 - 4228 or FDA at 1 - 800 - FDA - 1088 or www . fda . gov / medwatch .
8 USE IN SPECIFIC POPULATIONS SODIUM CITRATE 4 % W / V ANTICOAGULANT SOLUTION USP has not been adequately studied in controlled clinical trials with specific populations .
ANTICOAGULANT SOLUTION has not been studied in controlled clinical trials with specific populations .
11 DESCRIPTION SODIUM CITRATE 4 % W / V ANTICOAGULANT SOLUTION USP is designed to be metered by an apheresis device in apheresis procedures , to prevent platelet activation and coagulation as blood moves throughout the extracorporeal unit ( tubing set ) in an apheresis procedure .
The solution is sterile and non - pyrogenic , and it contains no bacteriostatic or antimicrobial agents .
The formulas of the active ingredients are provided in Table 1 .
Table 1 : Active IngredientsIngredients Molecular Formula Molecular Weight Sodium Citrate Dihydrate C6H9Na3O9 294 . 10 Water for Injection H2O 18 . 00 Each 100 mL of SODIUM CITRATE 4 % W / V ANTICOAGULANT SOLUTION USP contains : Sodium Citrate ( dihydrate ) 4 . 0 g ; and 100 mL Water for Injection ( pH adjusted with citric acid ) .
The PVC bag is not made with natural rubber latex .
The bag is made from a multilayered film .
It contains materials that have been tested to demonstrate the suitability of the container for storing pharmaceutical solutions .
The bag is nontoxic and biologically inert .
The bag - solution unit is a closed system and is not dependent upon entry of external air during administration .
The bag is overwrapped to provide protection from the physical environment and to provide an additional moisture barrier when necessary .
12 CLINICAL PHARMACOLOGY 12 . 1 Mechanism of Action SODIUM CITRATE 4 % W / V ANTICOAGULANT SOLUTION USP acts as an extracorporeal anticoagulant by binding the free calcium in the blood .
Calcium is a necessary co - factor to several steps in the clotting cascade .
The following ingredients are key components of the solution : • Citric acid for pH regulation • Sodium Citrate anticoagulant This solution has no pharmacological effect .
16 HOW SUPPLIED / STORAGE AND HANDLING SODIUM CITRATE 4 % W / V ANTICOAGULANT SOLUTION USP is a clear solution supplied in sterile and non - pyrogenic PVC bags .
The bags are packaged 30 bags per case .
SIZE CATALOG NUMBER NDC NUMBER 250 mL 40881 14537 - 881 - 25 STORAGE Up to 25 ° C . Protect from freezing .
Issued : August 2017 Manufactured by Terumo BCT , Inc .
Lakewood , CO 80215 PRINCIPAL DISPLAY PANEL - 250 mL Bag Carton Label Sodium Citrate 4 % w / v Anticoagulant Solution USP Catalog # 40881 30 x 250 mL units NDC 14537 - 881 - 25 For use only with automated apheresis procedures .
See apheresis device operator ' s manual for complete instructions .
Read the package insert before application .
Sterile .
Non - pyrogenic .
Sterilized with steam .
Caution : Do not use unless the solution is clear and the container is intact .
Single use container .
Discard any unused product .
Not for direct intravenous infusion .
Rx Only .
Recommended storage : Up to 25 ° C . Protect from freezing .
Each 100 mL contains : Sodium Citrate Dihydrate 4 . 0 g Water for Injection to ( pH adjusted with citric acid ) 100 mL Approximate Millimoles : Sodium Citrate 13 . 8 Manufactured by Terumo BCT , Inc . 10811 W . Collins Ave . , Lakewood CO 80215 , USA 777962 - 240 TERUMOBCT Lot Expiry Date [ MULTIMEDIA ] [ MULTIMEDIA ]
